A practical reference on pentapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required. The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations. It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination.
Unattended weather station recording (such as wind speed / direction, temperature, relative humidity, solar radiation). Unattended hydrographic recording (such as water level, water depth, water flow, water pH, water conductivity). Unattended soil moisture level recording. Unattended gas pressure recording. Offshore buoys for recording a variety of environmental conditions. Road traffic counting. Measure temperatures (humidity, etc.) of perishables during shipments: Cold chain. Measure variations in light intensity. Measuring temperature of pharmaceutical products, medicines and vaccines during storage Measuring temperature and humidity of perishable products during transportation to ensure cold chain is maintained Process monitoring for maintenance and troubleshooting applications. Process monitoring to verify warranty conditions Wildlife research with pop-up archival tags Measure vibration and handling shock (drop height) environment of distribution packaging. Tank level monitoring. Deformation monitoring of any object with geodetic or geotechnical sensors controlled by an automatic deformation monitoring system. Environmental monitoring. Vehicle testing (including crash testing) Motor racing Monitoring of relay status in railway signaling. For science education enabling 'measurement', 'scientific investigation' and an appreciation of 'change' Record trend data at regular intervals in veterinary vital signs monitoring. Load profile recording for energy consumption management. Temperature, humidity and power use for heating and air conditioning efficiency studies.
February 23, 2011 Venezuela Economists expressed concern with regards to Venezuela's economy improving due to instability in the private sector pressured by the socialist government, as José Guerra, former manager at the Central Bank of Venezuela, stated that private investment, accounting for half of Venezuela's GDP, dropped 2.2% in 2010.
== Prognosis == The availability of treatments that modify the course of multiple sclerosis beginning in the 1990s, known as disease-modifying therapies (DMTs), has improved prognosis. These treatments can reduce relapses and slow progression, but there is no cure. Before the advent of these medications, it took around 15 years before relapsing-remitting MS progressed to secondary progressive MS (which has associated mobility issues). With these medications, the progression is slower to 40 years. The prognosis of MS depends on the subtype of the disease, and there is considerable individual variation in the progression of the disease. In relapsing MS, the most common subtype, a 2016 cohort study found that after a median of 16.8 years from onset, one in ten needed a walking aid, and almost two in ten transitioned to secondary progressive MS, a form characterized by more progressive decline. With treatments available in the 2020s, relapses can be eliminated or substantially reduced. However, "silent progression" of the disease still occurs. In addition to secondary progressive MS (SPMS), a small proportion of people with MS (10–15%) experience progressive decline from the onset, known as primary progressive MS (PPMS). Most treatments have been approved for use in relapsing MS; there are fewer treatments with lower efficacy for progressive forms of MS. The prognosis for progressive MS is worse, with faster accumulation of disability, though with considerable individual variation.
=== mzML === Owing to the undesirability of having two formats (namely mzData and mzXML) representing the same information, a joint effort was set up by HUPO-PSI, the SPC/ISB, and instruments vendors to create a unified standard, borrowing the best aspects of both mzData and mzXML and intending to replace both. Originally called dataXML, it was officially announced as mzML. The first specification was published in June 2008. This format was officially released at the 2008 American Society for Mass Spectrometry Meeting, and has since then been relatively stable, having received very few updates. On 1 June 2009, mzML 1.1.0 was released. There were no further changes planned as of 2013.
Sources: en.wikipedia.org
== Development == A fruit results from the fertilizing and maturing of one or more flowers. The gynoecium, which contains the stigma-style-ovary system, is centered in the flower-head, and it forms all or part of the fruit. Inside the ovary(ies) are one or more ovules. Here begins a complex sequence called double fertilization: a female gametophyte produces an egg cell for the purpose of fertilization. (A female gametophyte is called a megagametophyte or embryo sac.) After double fertilization, the ovules become seeds. Ovules are fertilized in a process that starts with pollination, which is the movement of pollen from the stamens to the stigma-style-ovary system within the flower-head. After pollination, a pollen tube grows from the (deposited) pollen through the stigma down the style into the ovary to the ovule. Two sperm are transferred from the pollen to a megagametophyte. Within the megagametophyte, one sperm unites with the egg, forming a zygote, while the second sperm enters the central cell forming the endosperm mother cell, which completes the double fertilization process. Later, the zygote will give rise to the embryo of the seed, and the endosperm mother cell will give rise to endosperm, a nutritive tissue used by the embryo. Fruit formation is associated with meiosis, a central aspect of sexual reproduction in flowering plants. During meiosis homologous chromosomes replicate, recombine and randomly segregate, and then undergo segregation of sister chromatids to produce haploid cells.
Throughout the process, it is necessary to keep close control of the moisture content using a moisture meter system in order to reduce over-drying and allow operators to know when to pull the charge. Preferably, this in-kiln moisture meter will have an auto-shutoff feature.
== Career == Zaffaroni joined Syntex, then a small chemical company in Mexico, as a biochemist in 1951. He participated in turning Syntex into a major multinational pharmaceutical company, moving it to Palo Alto, California. He was appointed president of the U.S. subsidiary in 1962. In 1968, he founded ALZA, a syllabic abbreviation of his name, to develop medical treatments through controlled drug delivery. He modeled new delivery systems after the processes discovered in endocrinology – where glands deliver very small amounts of hormones but have a tremendous effect –. ALZA's first controlled drug delivery product was used to treat glaucoma. Other products that incorporated Zaffaroni's drug delivery technologies include Glucotrol, for non insulin-dependent diabetes; Duragesic, for management of severe chronic pain; NicoDerm CQ, for smoking cessation; and Transderm-Scop, to prevent nausea and vomiting associated with motion sickness. In 1980, Zaffaroni established DNAX, a developer of macromolecular products that combines the technologies of genetic engineering and immunobiology. In 1988 he co-founded Affymax, specializing in combinatorial chemistry to reduce the cost and time of identifying new medicines. In 1991 he co-founded Affymetrix, specializing in using genetics for developing new medicine. He was also involved in the creation of Perlegen Sciences, an Affymetrix spin-off which works on finding genetic causes of disease. In 1994, he founded Symyx Technologies, a company dedicated to utilizing combinatorial chemistry technologies.
In 2024, D'Souza criticized the International Olympic Committee (IOC), alleging institutional corruption and inadequate athlete compensation. He also advocated for the abolition of the World Anti-Doping Agency (WADA), characterizing it as an "anti-science" extension of the IOC. D'Souza also argued that the Olympic program includes insignificant sports. He states that he has never used performance-enhancing drugs himself. By late 2025, he had been replaced as chief executive by Maximilian Martin, investment banker and bitcoin miner. Olympians attached to the organisation as of 2023 include Brett Fraser, Roland Schoeman, and Christina Smith. In 2025, Brett Hawke was named head swim coach. Other people include geneticist George Church. German biotech billionaire Christian Angermayer is co-founder of the organisation. D'Souza became Thiel's confidant in the process of leading the Gawker plan for him, and through Thiel's introduction, a friend of Angermayer. According to The Spectator, in December 2022, as D'Souza and other members of their small community of gay tech founders were about to gather for the annual party at Thiel's residence in Miami (formerly held while travelling the world, until Thiel had children), D'Souza came up with the idea of the Enhanced Games. After receiving positive feedback from Thiel (while other investors thought that the idea was "outside the Overton window"), D'Souza spent the next six months developing the project. Later, after reading about the plan on German media, Angermayer notified D'Souza that he wanted to come on board as a co-founder.
Sources: en.wikipedia.org
One mode of monazite formation is crystallization from an igneous melt. The concentric zoning pattern reflects the changing composition of the melt which affects the composition of the crystallizing monazite.
Britain, France, the United States, Canada, and eight other Western European countries signed the North Atlantic Treaty of April 1949, establishing the North Atlantic Treaty Organization (NATO). That August, the first Soviet atomic device was detonated in Semipalatinsk, Kazakh SSR. Following Soviet refusals to participate in a German rebuilding effort set forth by western European countries in 1948, the US, Britain and France spearheaded the establishment of the Federal Republic of Germany from the three Western zones of occupation in April 1949. The Soviet Union proclaimed its zone of occupation in Germany the German Democratic Republic that October. Media in the Eastern Bloc was an organ of the state, completely reliant on and subservient to the communist party. Radio and television organizations were state-owned, while print media was usually owned by political organizations, mostly by the local communist party. Soviet radio broadcasts used Marxist rhetoric to attack capitalism, emphasizing themes of labor exploitation, imperialism and war-mongering. Along with the broadcasts of the BBC and the Voice of America to Central and Eastern Europe, a major propaganda effort began in 1949 was Radio Free Europe/Radio Liberty, dedicated to bringing about the peaceful demise of the communist system in the Eastern Bloc. Radio Free Europe attempted to achieve these goals by serving as a surrogate home radio station, an alternative to the controlled and party-dominated domestic press in the Soviet Bloc.
== Discovery == Aerographene was discovered in 2013 at Zhejiang University by a team of scientists led by Gao Chao. He and his team had already successfully created macroscopic materials made out of graphene. These materials were one-dimensional and two-dimensional. However, when synthesizing aerographene, the scientists instead created a three-dimensional structure. The synthesis was accomplished by the freeze-drying of carbon nanotube solutions and large amounts of graphene oxide. Residual oxygen was then removed chemically.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.